

Mead Johnson Celebrates IPO, First Day of Trading on NYSE

• *First Major IPO in 2009* •

• *NYSE Euronext #1 in Global IPO Proceeds Year-to-Date, Continuing Its IPO Lead from 2008* •

NEW YORK, Feb. 11, 2009 – Mead Johnson Nutrition Company today opened for trading on the New York Stock Exchange under the ticker symbol “MJN” after its successful IPO in which it raised \$7.2 million. Mead Johnson, with 2008 revenue of nearly \$2.9 billion, is a global leader in pediatric nutrition and best known for its Enfamil® infant formula and “Enfa” brand franchise.

Mead Johnson, based in Evansville, IN, is the first major U.S. company to go public in 2009 and the largest U.S. IPO since American Water Works (NYSE: AWK) listed on the NYSE on April 23, 2008.

“Mead Johnson is a well-respected global company and a welcome addition to our family of NYSE-listed companies,” said Scott R. Cutler, NYSE Euronext EVP and Head of Listings, Americas. “We look forward to providing the company with superior liquidity, services and brand visibility associated with listing on NYSE Euronext markets.”

“Mead Johnson Nutrition is pleased to be listed on NYSE Euronext and to become the first public company solely focused on pediatric nutrition,” said Chief Executive Officer Stephen W. Golsby. “We look forward to continuing our commitment to create products and brands trusted to give infants and children the best start in life.”

To celebrate the special occasion, Golsby rang today’s opening bell, joined by the company’s management committee.

Mead Johnson is formerly a division of Bristol-Myers Squibb Company, which is listed on the NYSE under the symbol “BMY.”

2008 IPOs on NYSE Euronext markets:

-- Based on IPO proceeds raised globally in 2008, NYSE Euronext retained its # 1 ranking among major exchanges globally, with \$45 billion raised, or 37% of total IPO capital proceeds.

-- In 2008, NYSE Euronext attracted the largest IPO in U.S. history, with **Visa** (NYSE: V), raising \$17.86 billion/€11.5 billion, and in Europe, the second-largest IPO in Europe in 2008, with **EDPR** (NYSE Euronext: EDPR) raising \$2.42 billion/€1.566 billion.

About Mead Johnson Nutrition (NYSE: MJN)

Mead Johnson is a global leader in pediatric nutrition. The company develops, manufactures, markets and distributes more than 70 products in 50 markets world wide primarily under the “Enfa” family of brands, including Enfamil® infant formula. Our mission is to create nutritional brands and products trusted to give infants and children the best start in life. For more information or to download company and brand images and footage, please visit www.meadjohnson.com.

About NYSE Euronext

NYSE Euronext (NYX) is the world’s leading, most liquid and diverse exchange group. It offers a broad and growing array of financial products and services in cash equities, futures, options, exchange-traded products, bonds, market data, and commercial technology solutions, all designed to meet the evolving needs of issuers, investors and financial institutions. Spanning multiple asset classes and six countries, NYSE Euronext’s exchanges include the New York Stock Exchange, Liffe, the leading European derivatives exchange by value of trading, Euronext and NYSE Arca. With more than 6,500 listed issues, more than any other exchange group, trading on NYSE Euronext’s equity markets represents more than one-third of the world’s cash equities volume. NYSE Euronext is part of the S&P 500 index and the only exchange operator in the S&P 100 index. For more information, please visit www.nyx.com.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning NYSE Euronext’s plans, objectives, expectations and intentions and other statements that are not historical or current facts. Forward-looking statements are based on NYSE Euronext’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause NYSE Euronext’s results to differ materially from current expectations include, but are not limited to: NYSE Euronext’s ability to implement its strategic initiatives, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk and U.S. and global competition, and other factors detailed in NYSE Euronext’s reference document for 2007 (“document de référence”) filed with the French Autorité des Marchés Financiers (Registered on May 15, 2008 under No. R. 08-054), 2007 Annual Report on Form 10-K and other periodic reports filed with the U.S. Securities and Exchange Commission or the French Autorité des Marchés Financiers. In addition, these statements are based on a number of assumptions that are subject to change. Accordingly, actual results may be materially higher or lower than those projected. The inclusion of such projections herein should not be regarded as a representation by NYSE Euronext that the projections will prove to be correct. This press release speaks only as of this date. NYSE Euronext disclaims any duty to update the information herein.